冠状动脉介入术后再狭窄药物预防治疗现状及进展  

Progress of Drugs Prevention and Treatment for Restenosis after Coronary Artery Intervention

作　　者：张新平 庞月华 冯义伯[2] 

机构地区：[1]新疆乌鲁木齐市友谊医院心内科,新疆乌鲁木齐830049 [2]华中科技大学同济医学院附属协和医院心内科,湖北武汉430022

出　　处：《心血管病学进展》2005年第4期366-370,共5页Advances in Cardiovascular Diseases

摘　　要：经皮冠状动脉成形术广泛应用于有症状冠心病患者,尽管初始疗效较好,但术后通常并发较高的再狭窄率。冠脉内支架的应用已使再狭窄率从50%下降至20%～30%,然而支架内再狭窄仍然是一个新的、棘手的问题。理想的药物治疗前途有望,但疗效有限。有些抗血栓药物可减少术后急性血栓形成和某些并发症,有些抗增殖药物在预防再狭窄中已显现出令人激动的前景。通过再狭窄病理生理学特点,综述冠状动脉介入术后药物治疗再狭窄的现状及进展。Percutaneous transluminal coronary angioplasty (PTCA) is widely used to treat patients with symptomatic coronary artery disease.Although usually initially successful,an angioplasty procedure can be complicated by a higher rate of restenosis.Coronary in-stents have reduced the rate of restenosis from 50% down to 20%~30%.However,in-stent restenosis presents a new challenging dilemma.The success of drugs therapy is promising,but very limited.Some antithrombotic agents have reduced acute thrombosis and many of the acute complications of angioplasty.Some antiproliferative drugs show excited new advance in preventing restenosis.This article reviews the progress of pharmacological therapies for restenosis after coronary artery intervention through pathophysiology of restenosis.

关 键 词：经皮冠状动脉成形术 支架 冠心病 再狭窄 药物治疗 

分 类 号：R541.4[医药卫生—心血管疾病]